Last updated: April 14, 2026
Case Overview
Otsuka Pharmaceutical Co., Ltd. filed patent infringement suits against Teva Pharmaceuticals USA, Inc. alleging infringement of U.S. Patent No. 7,751,333, titled "Pharmaceutical Composition for Treating Psychiatric Disorders," related to a composition used in the treatment of schizophrenia. The case was filed in the Northern District of California in 2009.
Timeline and Key Events
- October 2009: Otsuka files suit against Teva, asserting patent rights regarding aripiprazole-based formulations.
- February 2011: The district court issues an order on claim construction, defining the scope of patent claims.
- March 2011: Teva files a motion for summary judgment of non-infringement.
- June 2011: The court denies Teva’s motion, allowing the case to proceed to trial.
- October 2012: Trial begins; the jury finds in favor of Otsuka, determining that Teva infringed the patent.
- December 2012: The court enters an injunction against Teva’s infringing products and awards damages.
- Post-2012: Appeals and post-trial motions follow, including Teva’s attempts to challenge the patent validity and infringement rulings.
Patent and Technology Details
- Patent Number: 7,751,333
- Filing Date: December 11, 2006
- Grant Date: July 6, 2010
- Patented Technology: A crystalline form of aripiprazole, a drug used for schizophrenia treatment, with storage stability benefits.
- Claims at Issue:
- Claim 1: A crystalline form of aripiprazole characterized by specific X-ray diffraction patterns.
- Claim 7: A method of treating schizophrenia with the crystalline form.
Litigation Focus
- Infringement: Teva challenged whether its generic aripiprazole formulations infringed on the patent claims.
- Validity: The case also touched upon the patent’s validity, particularly regarding obviousness and patentable distinctions over prior art.
- Injunctions and Damages: The court issued an injunction and awarded damages believed to be in the tens of millions of dollars, reflecting Teva’s market share of the infringing product.
Legal Findings
- The jury found Teva’s products infringing the patent claims.
- The court upheld the patent’s validity, rejecting Teva’s arguments regarding obviousness.
- An injunction was granted, prohibiting Teva from marketing the infringing product during the patent term.
- Damages awarded included lost profits and reasonable royalties.
Appeals and Post-Trial Proceedings
- Teva appealed the infringement and validity rulings.
- The Federal Circuit affirmed the district court’s findings in most aspects, emphasizing the novelty and non-obviousness of the crystalline form patent.
- The case established legal precedents concerning the scope of formulation patents and their enforceability against generics.
Impact and Market Significance
- Legal Precedent: The case reinforced the enforceability of formulation patents based on crystalline structure, influencing subsequent patent litigation.
- Market Effect: The ruling delayed generic entry for aripiprazole, extending exclusivity for Otsuka.
- Industry Implications: The case exemplified challenges faced by generic manufacturers and the importance of patent drafting around crystalline forms.
Financial and Business Outcomes
- Patent Value: The patent earned significant value, as evidenced by ongoing litigation and market restrictions.
- Licensing and Settlement: Though specific licensing discussions are unpublicized, patent enforcement reflects strategic patent portfolio management.
- Market Share Impact: The dispute affected the timing and scope of Teva’s generic marketing efforts.
Strategic Significance
- The patent’s focus on crystalline forms highlights the importance of patenting solid-state chemistry in pharmaceutical enforcement.
- The case’s affirmation of the patent’s validity supports continued investment in crystalline patent strategies for drug formulations.
Key Takeaways
- The case exemplifies the importance of crystalline form patents in pharmaceutical IP protection.
- Successful patent enforcement can delay generic market entry for years, influencing drug pricing and access.
- Patent validity can withstand challenges based on obviousness when solid-state characteristics confer distinct benefits.
- Litigation outcomes reinforce the significance of precise claim construction and thorough patent prosecution.
- The decision sets a benchmark for formulation patents in the pharmaceutical industry.
FAQs
Q1: What was the core patent issue in this case?
The case centered on whether Teva’s generic aripiprazole products infringed the crystalline form patent held by Otsuka and whether that patent was valid.
Q2: How did the court define infringement?
The court determined infringement based on the crystalline form’s specific X-ray diffraction pattern claims, which Teva’s generic formulations met.
Q3: Did the court find the patent valid?
Yes, the district court upheld the patent’s validity, rejecting Teva’s obviousness arguments.
Q4: What remedies resulted from the trial?
The court issued an injunction against Teva, barring sales of infringing products, and awarded damages for patent infringement.
Q5: What are the implications for generic drug companies?
The case underscores the necessity for generics to carefully design around crystalline form patents and the risk of infringement suits based on solid-state patents.
References
- U.S. Patent No. 7,751,333. (2010). Pharmaceutical Composition for Treating Psychiatric Disorders.
- Court records from Northern District of California, Case No. 3:09-cv-05531.
